What is the main advantage of CGRP monoclonal antibodies for long-term migraine control?

What is the main advantage of CGRP monoclonal antibodies for long-term migraine control?

• A. Long-acting, convenient dosing with substantial reduction in monthly migraine days for many patients; generally well tolerated.
• B. They cure migraine completely in all patients
• C. They are inexpensive and require no follow-up
• D. They often cause intolerable side effects

Answer: (A)

The main concept tested is that CGRP monoclonal antibodies offer durable, convenient prevention for migraine with a favorable safety profile. These therapies are given less frequently (monthly or quarterly, depending on the agent) because they have long-lasting effects after each dose. By specifically targeting the CGRP pathway, they reduce the neurovascular processes that drive migraine attacks, leading to substantial decreases in monthly migraine days for many patients. This combination of powerful, sustained preventive effect and relatively easy administration improves adherence and long-term control, which is the core advantage over daily oral preventives that can have more systemic side effects and adherence challenges. They do not cure migraine in every patient, and ongoing treatment is typically needed to maintain benefit. They can be expensive and do require follow-up to monitor response and any adverse effects, but these factors don’t negate the primary advantage of reduced attack frequency with convenient dosing. They are not associated with intolerable side effects in most people, and while monitoring is part of routine care, the overall safety profile is generally favorable. So the option describing long-acting, convenient dosing with substantial reduction in monthly migraine days for many patients and generally good tolerability best captures the main advantage.

The main concept tested is that CGRP monoclonal antibodies offer durable, convenient prevention for migraine with a favorable safety profile. These therapies are given less frequently (monthly or quarterly, depending on the agent) because they have long-lasting effects after each dose. By specifically targeting the CGRP pathway, they reduce the neurovascular processes that drive migraine attacks, leading to substantial decreases in monthly migraine days for many patients. This combination of powerful, sustained preventive effect and relatively easy administration improves adherence and long-term control, which is the core advantage over daily oral preventives that can have more systemic side effects and adherence challenges.

They do not cure migraine in every patient, and ongoing treatment is typically needed to maintain benefit. They can be expensive and do require follow-up to monitor response and any adverse effects, but these factors don’t negate the primary advantage of reduced attack frequency with convenient dosing. They are not associated with intolerable side effects in most people, and while monitoring is part of routine care, the overall safety profile is generally favorable.

So the option describing long-acting, convenient dosing with substantial reduction in monthly migraine days for many patients and generally good tolerability best captures the main advantage.